Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

Circulation

Volumn 103, Issue 24, 2001, Pages 2885-2890

  Vasa, Mariuca ^a   Fichtlscherer, Stephan ^a   Adler, Klaudia ^a   Aicher, Alexandra ^a   Martin, Hans ^a   Zeiher, Andreas M ^a   Dimmeler, Stefanie ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Coronary disease; Endothelium

Indexed keywords

ATORVASTATIN; CD34 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL;

EID: 0035912855     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc2401.092816     Document Type: Article

References (32)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
4. Current perspectives on statins
5. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
6. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction
7. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
8. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
9. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
10. Angiogenesis in cancer, vascular, rheumatoid and other disease
11. Isolation of putative progenitor endothelial cells for angiogenesis
12. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
13. Mechanisms of angiogenesis
14. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
15. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
16. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
17. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells
18. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors
19. Evidence for circulating bone marrow-derived endothelial cells
20. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects
21. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo
22. Early expression of angiogenesis factors in acute myocardial ischemia and infarction
23. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization
24. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice
25. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
26. Activation of nitric oxide synthase in endothelial cells via Akt-dependent phosphorylation
27. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
28. Phosphorylation of the endothelial nitric oxide synthase at Ser 1177 is required for VEGF-induced endothelial cell migration
29. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt
30. Akt takes center stage in angiogenesis signaling
31. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
32. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial